Targets › RT
7 programs from 3 companies in 67 trials: 24 Phase 3, 20 Phase 2, 17 Phase 4, 6 Phase 1; Infectious disease, Oncology, Metabolic and endocrine; next expected readout Mar 2027.
Open in Phaseline: the race on RT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| GSK | Dolutegravir Human immunodeficiency virus type 1 integrase inhibitor | INSTI, RTASE, INTEGRASE, RT | Phase 3 | HIV; HIV Infections; HIV-1-infection; Acute HIV Infection … | Mar 2027 |
| GSK | Lamivudine Human immunodeficiency virus type 1 reverse transcriptase inhibitor; DNA polymerase/reverse transcriptase inhibitor | RT | Phase 3 | HIV; HIV Infection; HIV Prevention; Pre-exposure Prophylaxis … | Mar 2027 |
| Merck & Co. (MSD) | Islatravir Reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor | POLG, RT | Phase 3 | HIV-1 Infection; HIV Infection; Human Immunodeficiency Virus Type 1 (HIV-1) Infection | Aug 2027 |
| Gilead Sciences | Islatravir Reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor | RT, IN, POLB, INTS1, INTS8 | Phase 3 | HIV-1-Infection; HIV-1-infection; HIV-1 Infection | Mar 2028 |
| GSK | Rilpivirine Human immunodeficiency virus type 1 reverse transcriptase inhibitor | RT | Phase 3 | HIV Infections; Infection, Human Immunodeficiency Virus; HIV-1 Infected Adults With Controlled Viremia; HIV -1 Infection … | Jun 2028 |
| Merck & Co. (MSD) | Doravirine Human immunodeficiency virus type 1 reverse transcriptase negative allosteric modulator | RT, POLA2, POLG | Phase 3 | HIV-1 Infection; Human Immunodeficiency Virus (HIV) Infection; HIV-1-infection; HIV … | Jul 2028 |
| Gilead Sciences | Tenofovir Alafenamide Human immunodeficiency virus type 1 reverse transcriptase inhibitor | POLRMT, RT | Phase 2 | Acquired Immune Deficiency Syndrome (AIDS); Chronic Hepatitis B; Hepatitis B Reactivation; Chronic Hepatitis b … | Mar 2027 |
HIV-1-infection (13) HIV-1 Infection (7) HIV Infections (7) HIV (5) Chronic Hepatitis b (3) HIV Infection (2) Human Immunodeficiency Virus Type 1 (HIV-1) Infection (2) Human Immunodeficiency Virus (HIV) Infection (2) Hepatitis B (2) HIV-1-Infection (1) Acute HIV Infection (1) Healthy Volunteer (1)
small molecule (6), mixed (1)
GSK (3) Gilead Sciences (2) Merck & Co. (MSD) (2)
POLG (2) IN (1) POLB (1) INTS1 (1) INTS8 (1) INSTI (1) RTASE (1) INTEGRASE (1) POLA2 (1) POLRMT (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.